A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.
Yacoub MS, El-Nakhal T, Hasabo EA, Shehata N, Wilson K, Ismail KH, Bakr MS, Mohsen M, Mohamed A, Abdelazim E, Ali HT, Soliman Z, Sayed A, Abdelsayed K, Caliskan K, Soliman O.
Yacoub MS, et al.
Heart Fail Rev. 2024 Mar;29(2):479-496. doi: 10.1007/s10741-023-10375-6. Epub 2023 Dec 19.
Heart Fail Rev. 2024.
PMID: 38112937
Review.
Hypertrophic cardiomyopathy (HCM) is the most common heritable myocardial disorder worldwide. ...Mavacamten showed a statistically significant increase in the frequency of the primary composite endpoint (RR = 1.92, 95% CI [1.28, 2.88]), 1 NYHA class improveme …
Hypertrophic cardiomyopathy (HCM) is the most common heritable myocardial disorder worldwide. ...Mavacamten showed a statistic …